Your browser doesn't support javascript.
loading
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).
Sanoja-Flores, L; Flores-Montero, J; Garcés, J J; Paiva, B; Puig, N; García-Mateo, A; García-Sánchez, O; Corral-Mateos, A; Burgos, L; Blanco, E; Hernández-Martín, J; Pontes, R; Díez-Campelo, M; Millacoy, P; Rodríguez-Otero, P; Prosper, F; Merino, J; Vidriales, M B; García-Sanz, R; Romero, A; Palomera, L; Ríos-Tamayo, R; Pérez-Andrés, M; Blanco, J F; González, M; van Dongen, J J M; Durie, B; Mateos, M V; San-Miguel, J; Orfao, A.
Afiliación
  • Sanoja-Flores L; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.
  • Flores-Montero J; Centro de Investigación Biomédica en Red de Cáncer: CIBER-ONC number CB16/12/00400, Instituto Carlos III, Madrid, Spain.
  • Garcés JJ; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.
  • Paiva B; Centro de Investigación Biomédica en Red de Cáncer: CIBER-ONC number CB16/12/00400, Instituto Carlos III, Madrid, Spain.
  • Puig N; Clinica Universidad de Navarra (UNAV), Applied Medical Research Center (CIMA), IDISNA. CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
  • García-Mateo A; Clinica Universidad de Navarra (UNAV), Applied Medical Research Center (CIMA), IDISNA. CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
  • García-Sánchez O; Department of Hematology, University Hospital of Salamanca (HUSA), IBSAL; IBMCC (USAL-CSIC). CIBER-ONC number CB16/12/00233, Salamanca, Spain.
  • Corral-Mateos A; Department of Hematology, Health Care Center of Segovia (CAS), Segovia, Spain.
  • Burgos L; Department of Hematology, University Hospital of Salamanca (HUSA), IBSAL; IBMCC (USAL-CSIC). CIBER-ONC number CB16/12/00233, Salamanca, Spain.
  • Blanco E; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.
  • Hernández-Martín J; Centro de Investigación Biomédica en Red de Cáncer: CIBER-ONC number CB16/12/00400, Instituto Carlos III, Madrid, Spain.
  • Pontes R; Clinica Universidad de Navarra (UNAV), Applied Medical Research Center (CIMA), IDISNA. CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
  • Díez-Campelo M; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.
  • Millacoy P; Centro de Investigación Biomédica en Red de Cáncer: CIBER-ONC number CB16/12/00400, Instituto Carlos III, Madrid, Spain.
  • Rodríguez-Otero P; Department of Hematology, Health Care Center of Segovia (CAS), Segovia, Spain.
  • Prosper F; Faculty of Medicine, Federal University of Rio de Janeiro and Institute of Pediatrics and Childhood Care, Rio de Janeiro, Brazil.
  • Merino J; Department of Hematology, University Hospital of Salamanca (HUSA), IBSAL; IBMCC (USAL-CSIC). CIBER-ONC number CB16/12/00233, Salamanca, Spain.
  • Vidriales MB; Department of Hematology, Hospital Center of Navarra (CHN), Pamplona, Spain.
  • García-Sanz R; Clinica Universidad de Navarra (UNAV), Applied Medical Research Center (CIMA), IDISNA. CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
  • Romero A; Clinica Universidad de Navarra (UNAV), Applied Medical Research Center (CIMA), IDISNA. CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
  • Palomera L; Clinica Universidad de Navarra (UNAV), Applied Medical Research Center (CIMA), IDISNA. CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
  • Ríos-Tamayo R; Department of Hematology, University Hospital of Salamanca (HUSA), IBSAL; IBMCC (USAL-CSIC). CIBER-ONC number CB16/12/00233, Salamanca, Spain.
  • Pérez-Andrés M; Department of Hematology, University Hospital of Salamanca (HUSA), IBSAL; IBMCC (USAL-CSIC). CIBER-ONC number CB16/12/00233, Salamanca, Spain.
  • Blanco JF; Primary Care Center Miguel Armijo, Sanidad de Castilla y León (SACYL), Salamanca, Spain.
  • González M; Department of Hematology, University Hospital Lozano Blesa (HULB), Zaragoza, Spain.
  • van Dongen JJM; Department of Hematology, Virgen de las Nieves Hospital (HVN), Granada, Spain.
  • Durie B; Cancer Research Center (IBMCC-CSIC/USAL-IBSAL); Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.
  • Mateos MV; Centro de Investigación Biomédica en Red de Cáncer: CIBER-ONC number CB16/12/00400, Instituto Carlos III, Madrid, Spain.
  • San-Miguel J; Department of Orthopedics, University Hospital of Salamanca, IBSAL; IBMCC (USAL-CSIC), Salamanca, Spain.
  • Orfao A; Department of Hematology, University Hospital of Salamanca (HUSA), IBSAL; IBMCC (USAL-CSIC). CIBER-ONC number CB16/12/00233, Salamanca, Spain.
Blood Cancer J ; 8(12): 117, 2018 11 19.
Article en En | MEDLINE | ID: mdl-30455467
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células Plasmáticas / Gammopatía Monoclonal de Relevancia Indeterminada / Citometría de Flujo / Mieloma Múltiple / Células Neoplásicas Circulantes Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Blood Cancer J Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células Plasmáticas / Gammopatía Monoclonal de Relevancia Indeterminada / Citometría de Flujo / Mieloma Múltiple / Células Neoplásicas Circulantes Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Blood Cancer J Año: 2018 Tipo del documento: Article